GARFIELD HEIGHTS, Ohio--(BUSINESS WIRE)-- AxioMed® Spine Corporation (www.axiomed.com), a spinal orthopedics company focused on the development of products designed to restore spinal function in patients with degenerative spine disease by advancing the standard of care beyond fusion and first generation total disc replacement, announced today that it has completed a new round of financing, raising $3.6 million from current and new investors.
About AxioMed® Spine Corporation
AxioMed’s mission is to develop products focused on spinal function for patients with degenerative spine disease, thus advancing the standard of care beyond fusion and first generation total disc replacement. The Company’s leading products, the Freedom® Lumbar and Cervical Discs, were developed and designed by a team of clinicians and experts in the fields of biomechanics, pathology, spinal surgery and polymer science. The Freedom Lumbar and Cervical Discs have received CE Mark approval for distribution in the European Union. Additionally, the Company is pursuing US regulatory approval for its Freedom technology. Focusing on restoration of the natural function of the spine, AxioMed will enhance human health through research, innovation, development and service world-wide. For more information about AxioMed, please visit our website at www.axiomed.com.
AxioMed ® Spine Corporation
Gerald Baty, Chief Financial Officer, 216-587-5566